|
|
|
||
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||
|
Soliciting material pursuant to Rule 14a–12 under the Exchange Act
(17 CFR 240.14a–12)
|
|
Pre-commencement communications pursuant to Rule 14d–2(b) under
the Exchange Act (17 CFR 240.14d–2(b))
|
||
Pre-commencement communications pursuant to Rule 13e–4(c) under
the Exchange Act (17 CFR 240.13e–4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Emerging growth company
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
|
ADVERUM BIOTECHNOLOGIES, INC.
|
||
Date: August 10, 2021
|
By:
|
/s/ Laurent Fischer
|
Laurent Fischer, M.D.
|
||
President and Chief Executive Officer
|